AI Article Synopsis
- The study aimed to compare the effectiveness of two medication combinations, losartan/chlorthalidone and losartan/hydrochlorothiazide, in lowering blood pressure in patients with mild-to-moderate hypertension.
- Both treatments showed significant reductions in systolic and diastolic blood pressure after four weeks, with no significant differences in effectiveness or side effects between the two groups.
- The findings suggest that the losartan/chlorthalidone combination is a viable and effective alternative to the more commonly used losartan/hydrochlorothiazide for managing hypertension.
Article Abstract
Objective: The relationship of blood pressure (BP) to cardiovascular risk is linear, positive, and continuous. Lowering elevated BP reduces the risk of cardiovascular events. The primary objective of this randomized, multicenter, comparative, 3-month, open-label study was to evaluate the antihypertensive efficacy of losartan/chlorthalidone versus losartan/hydrochlorothiazide in mild-to-moderate essential hypertension.
Methods: A total of 137 eligible patients underwent a 2-week placebo washout period, following which 131 patients were randomized to losartan (L) 25mg/chlorthalidone (C) 6.25 mg (66/131) or to losartan 25 mg/hydrochlorothiazide (H) 12.5 mg (65/131) at three centers. Patients not responding after 4 weeks of therapy were escalated to losartan 25 mg/chlorthalidone 12.5 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg, respectively.
Results: Both treatment groups were similar with respect to demography and baseline characteristics. Altogether, 120 patients completed the study. After 4 weeks of therapy, both treatments showed a significant fall from baseline in systolic BP (SBP) and diastolic BP (DBP) (L/C: -20.17/-10.30; L/H: -17.63/-10.20). Both treatments were similar with respect to mean fall in SBP (p = 0.258), DBP (p = 0.934) and response rate (p = 0.769). Both step-up therapies were similar with respect to mean fall in SBP (p = 0.418), DBP (p = 0.389) from baseline and response rate (p = 0.769). All reported adverse events were of mild-to-moderate intensity, except for two serious AEs that occurred in patients who received L/H.
Conclusions: The losartan/low-dose chlorthalidone (6.25 mg) combination is as effective as the widely used losartan/hydrochlorothiazide combination in lowering BP and is well tolerated, thus providing a useful therapeutic option for treating mild-to-moderate hypertension.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14656560902991514 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial.
Trials
March 2011
Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Background: Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events.
View Article and Find Full Text PDFBaseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Hypertension
January 2001
Berman Center for Outcomes and Clinical Research and Hennepin County Medical Center (R.H.G., K.L.M.), Minneapolis, Minn.
-Diuretics and ss-blockers have been shown to reduce the risk of cardiovascular morbidity and mortality in people with hypertension in long-term clinical trials. No study has compared newer more costly antihypertensive agents (calcium antagonists, ACE inhibitors, and alpha-adrenergic blockers) with diuretics for reducing the incidence of cardiovascular disease in an ethnically diverse group of middle-aged and elderly hypertensive patients. The study is a randomized, double-blind, active-controlled clinical trial designed to determine whether the incidence of the primary outcome, fatal coronary heart disease or nonfatal myocardial infarction, differs between treatment initiation with a diuretic versus each of 3 other antihypertensive drugs.
View Article and Find Full Text PDFContext: Hypertension is associated with a significantly increased risk of morbidity and mortality. Only diuretics and beta-blockers have been shown to reduce this risk in long-term clinical trials. Whether newer antihypertensive agents reduce the incidence of cardiovascular disease (CVD) is unknown.
View Article and Find Full Text PDF[Effect of diuretics on serum lipoproteins].
Fortschr Med
November 1992
Medizinische Klinik II, Klinikum Grosshadern, Universität München.
Unlabelled: BASICS: Drug treatment of the risk factor hypertension has not led to the expected reduction in morbidity and mortality of coronary arterial disease. A negative effect of antihypertensive drugs on the lipid metabolism is under discussion as a possible cause.
Main Topics: Both the commonly employed thiazide diuretics and chlorthalidone and the loop diuretics furosemide, piretanide and xipamide lead, to varying extents, to an increase in total and LDL cholesterol as well as triglycerides in subjects with normal metabolism.
[Tablet strength and dosage of thiazides in hypertension must be reduced].
Tidsskr Nor Laegeforen
May 1991
Institutt for farmakoterapi, Universitetet i Oslo.
A number of studies indicate that hydrochlorothiazide doses above 50 mg daily provide little additional hypotensive effect but progressively greater hypokalemic effect. From these and similar studies on other thiazides a daily dose range for thiazides of 12.5-50 mg for hydrochlorothiazide, 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!